[Articles] Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials
This is an editorial summary of research originally reported by The Lancet. ProductSafer does not claim ownership of the underlying research. All intellectual property belongs to the original publishers.
Oral semaglutide was not efficacious in slowing clinical progression in participants with early Alzheimer's disease. Safety and tolerability of semaglutide in early Alzheimer's disease is consistent with studies in other indications.
Oral semaglutide was not efficacious in slowing clinical progression in participants with early Alzheimer's disease. Safety and tolerability of semaglutide in early Alzheimer's disease is consistent with studies in other indications.
This summary is based on reporting by The Lancet. For the complete article and full research details, see the original report linked below.
What you can do
- ✓If you or a family member have early-stage Alzheimer's disease, do not expect oral semaglutide (a GLP-1 receptor agonist medication) to slow cognitive decline, as recent clinical trials found it was not effective for this purpose.
- ✓Talk with your neurologist or primary care doctor about alternative treatments specifically studied for early Alzheimer's disease rather than relying on semaglutide as a disease-slowing therapy.
- ✓If you are currently taking semaglutide for diabetes or weight management and have concerns about Alzheimer's disease risk, discuss with your prescriber whether continuing this medication makes sense for your specific health situation, since it has not been shown to prevent or slow Alzheimer's progression.
Always consult a healthcare professional for personal medical advice.
Read the full report at the original source
The LancetWas this finding useful?